{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:55:36Z","timestamp":1790146536764,"version":"4.0.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T00:00:00Z","timestamp":1466121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81272335"],"award-info":[{"award-number":["81272335"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective.<\/jats:title>\n                  <jats:p>The study aimed to evaluate the value of the Cervista human papillomavirus (HPV), Hybrid Capture 2 (HC-2), and careHPV tests in diagnosing cervical intraepithelial neoplasia grade 2 (CIN2) or worse in Xinjiang Uyghur women.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>Three high-risk human papillomavirus (HR-HPV) detection methods were studied on two different populations by different combination modes; a cytology specimen was obtained at the same time. An abnormal result of any test resulted in referral to colposcopy. Cervical biopsy was also performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>In population 1, HR-HPV-positive rates were 57.6% and 54.3% as detected by HC-2 and Cervista, respectively; \u03ba = 0.892 for consistency check of HC-2 and Cervista (p &amp;lt; .001). Area under the receiver operating characteristic curve (AUC) of HC-2 and Cervista was 0.744 (95% confidence interval [CI]: 0.664\u223c0.824, p &amp;lt; .001) and 0.786 (95% CI: 0.715\u223c0.858, p &amp;lt; .001), respectively, for diagnosing CIN2+. The A9 probe can detect six subtypes of HPV, including HPV16, HPV31, HPV33, HPV35, HPV52, and HPV58. If one or more of these subtypes are postitive, then A9 will be positive. A diagnosis of class A9 by the Cerevista test correlated with pathological interpretations (chi-square = 43.063, p &amp;lt; .001). In population 2, HR-HPV-positive rates were 40.1% and 34.4%, respectively, by HC-2 and careHPV; \u03ba value was 0.779 for the two tests (p &amp;lt; .001). AUC of HC-2 was 0.895 (95% CI: 0.849\u223c0.940, p &amp;lt; .001), and careHPV was 0.841 (95% CI: 0.770\u223c0.899, p &amp;lt; .001) for diagnosing CIN2+.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Good consistency was shown between HC-2 and Cervista tests and also between the HC-2 and careHPV tests. In the detection of CIN2+, Cervista showed better specificity than HC-2, and interpretation of the A9 subgroup showed high predicted value. The HC-2 test demonstrated better sensitivity than careHPV in detection of CIN2+. HC-2, Cervista, and careHPV may be applied as a triage test for visual inspection with acetic acid\/Lugol\u2019s iodine-positive or ThinPrep cytologic test-positive women. The careHPV test was comparatively economical and efficient and may be more suitable for resource-limited regions, such as Xinjiang.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2015-0447","type":"journal-article","created":{"date-parts":[[2016,6,18]],"date-time":"2016-06-18T01:54:01Z","timestamp":1466214841000},"page":"825-831","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation of careHPV, Cervista Human Papillomavirus, and Hybrid Capture 2 Methods in Diagnosing Cervical Intraepithelial Neoplasia Grade 2+ in Xinjiang Uyghur Women"],"prefix":"10.1093","volume":"21","author":[{"given":"Gulixian","family":"Tuerxun","sequence":"first","affiliation":[{"name":"Fifth Department of Gynecology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uyghur, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awaguli","family":"Yukesaier","sequence":"additional","affiliation":[{"name":"Fifth Department of Gynecology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uyghur, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Lu","sequence":"additional","affiliation":[{"name":"Fifth Department of Gynecology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uyghur, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailibinuer","family":"Aierken","sequence":"additional","affiliation":[{"name":"Fifth Department of Gynecology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uyghur, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patiman","family":"Mijiti","sequence":"additional","affiliation":[{"name":"Fifth Department of Gynecology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uyghur, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, 12th Hospital of Xi\u2019an City, Xi\u2019an, Shaanxi, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axianguli","family":"Abulizi","sequence":"additional","affiliation":[{"name":"Clinical Laboratory Center, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uyghur, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Fifth Department of Gynecology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uyghur, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guzhanuer","family":"Abuduxikuer","sequence":"additional","affiliation":[{"name":"Fifth Department of Gynecology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uyghur, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guzhalinuer","family":"Abulizi","sequence":"additional","affiliation":[{"name":"Fifth Department of Gynecology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uyghur, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[{"name":"Fifth Department of Gynecology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uyghur, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,6,17]]},"reference":[{"key":"2021122309580519300_B1","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1016\/j.ejca.2009.07.018","article-title":"Trends of cervical cancer mortality in the member states of the European Union","volume":"45","author":"Arbyn","year":"2009","journal-title":"Eur J Cancer"},{"issue":"suppl 5","key":"2021122309580519300_B2","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"Forman","year":"2012","journal-title":"Vaccine"},{"key":"2021122309580519300_B3","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1001\/jama.285.11.1500","article-title":"Interobserver reproducibility of cervical cytologic and histologic interpretations: Realistic estimates from the ASCUS-LSIL Triage Study","volume":"285","author":"Stoler","year":"2001","journal-title":"JAMA"},{"key":"2021122309580519300_B4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"2021122309580519300_B5","volume-title":"Human Papillomavirus","author":"World Health Organization and IARC","year":"2005"},{"key":"2021122309580519300_B6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2006.07.031","article-title":"Clinical utility of HPV genotyping","volume":"103","author":"Meijer","year":"2006","journal-title":"Gynecol Oncol"},{"key":"2021122309580519300_B7","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1056\/NEJMoa0808516","article-title":"HPV screening for cervical cancer in rural India","volume":"360","author":"Sankaranarayanan","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122309580519300_B8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ijc.20076","article-title":"POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: Design, methods and baseline data of 44,102 women","volume":"110","author":"Bulkmans","year":"2004","journal-title":"Int J Cancer"},{"key":"2021122309580519300_B9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(09)70360-2","article-title":"Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: A randomised controlled trial","volume":"11","author":"Ronco","year":"2010","journal-title":"Lancet Oncol"},{"issue":"suppl 3","key":"2021122309580519300_B10","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S1386-6532(02)00187-7","article-title":"Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail","volume":"25","author":"Poljak","year":"2002","journal-title":"J Clin Virol"},{"key":"2021122309580519300_B11","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1128\/JCM.01833-07","article-title":"Detection of high-risk papillomavirus DNA with commercial invader-technology-based analyte-specific reagents following automated extraction of DNA from cervical brushings in ThinPrep media","volume":"45","author":"Schutzbank","year":"2007","journal-title":"J Clin Microbiol"},{"key":"2021122309580519300_B12","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1128\/JCM.00824-08","article-title":"Human papillomavirus genotype specificity of hybrid capture 2","volume":"46","author":"Castle","year":"2008","journal-title":"J Clin Microbiol"},{"key":"2021122309580519300_B13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jmoldx.2010.11.016","article-title":"Clinical experience with the Cervista HPV HR assay correlation of cytology and HPV status from 56,501 specimens","volume":"13","author":"Youens","year":"2011","journal-title":"J Mol Diagn"},{"key":"2021122309580519300_B14","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0002-9378(03)00418-6","article-title":"Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance","volume":"188","author":"ASCUS-LSIL Traige Study (ALTS) Group","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"2021122309580519300_B15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/jnci\/95.1.46","article-title":"Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: A 10-year cohort analysis","volume":"95","author":"Sherman","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2021122309580519300_B16","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ejca.2006.11.013","article-title":"HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology","volume":"43","author":"Ronco","year":"2007","journal-title":"Eur J Cancer"},{"key":"2021122309580519300_B17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/jnci\/94.2.102","article-title":"Effects of age and human papilloma viral load on colposcopy triage: Data from the randomized Atypical Squamous Cells of Undetermined Significance\/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS)","volume":"94","author":"Sherman","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2021122309580519300_B18","first-page":"2647","article-title":"Experience on screening of women\u2019s disease","volume":"21","author":"Jiang","year":"2006","journal-title":"Maternal Child Health Care China"},{"key":"2021122309580519300_B19","article-title":"The analysis of cervical cancer screening and the awareness of early detection and treatment of cervical cancer among women in Shenzhen [in Chinese]","volume":"40","author":"Li","year":"2013","journal-title":"Mod Prevent Med"},{"key":"2021122309580519300_B20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1750-9378-6-2","article-title":"Distribution of high and low risk HPV types by cytological status: A population based study from Italy","volume":"6","author":"Giorgi Rossi","year":"2011","journal-title":"Infect Agent Cancer"},{"key":"2021122309580519300_B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13510","article-title":"ARTISTIC: A randomised trial of human papillomavirus (HPV) testing in primary cervical screening","volume":"13","author":"Kitchener","year":"2009","journal-title":"Health Technol Assess"},{"key":"2021122309580519300_B22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1309\/RNF3C01JKADQCLKP","article-title":"The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays","volume":"127","author":"Stoler","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"2021122309580519300_B23","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ajog.2007.07.047","article-title":"2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests","volume":"197","author":"Wright","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"2021122309580519300_B24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcv.2014.01.015","article-title":"Comparison of the AnyplexII HPV 28 assay with the Hybrid Capture 2 assay for the detection of HPV infection","volume":"59","author":"Kwon","year":"2014","journal-title":"J Clin Virol"},{"key":"2021122309580519300_B25","first-page":"149","article-title":"High risk human papilloma-virus DNA detection kit (Cervista HPV HR) should be highly validated clinically in cervical cancer screening programs [in Chinese]","volume":"25","author":"Zhao","year":"2011","journal-title":"Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi"},{"key":"2021122309580519300_B26","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijid.2008.06.017","article-title":"Prevalence of human papillomavirus type 16 and its variants in abnormal squamous cervical cells in Northeast Thailand","volume":"13","author":"Chopjitt","year":"2009","journal-title":"Int J Infect Dis"},{"key":"2021122309580519300_B27","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jasc.2014.09.004","article-title":"The efficacy of HPV16\/18 genotyping in predicting CIN2+ in women with HPV+\/Pap results","volume":"3","author":"Khanna","year":"2014","journal-title":"J Am Soc Cytopathol"},{"key":"2021122309580519300_B28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jviromet.2014.02.002","article-title":"Human papillomavirus detection and genotyping, by HC2, full-spectrum HPV and molecular beacon real-time HPV assay in an Irish colposcopy clinic","volume":"201","author":"Keegan","year":"2014","journal-title":"J Virol Methods"},{"issue":"suppl 1","key":"2021122309580519300_B29","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.ygyno.2010.12.296","article-title":"Rapid high-risk human papillomavirus test shows excellent agreement with standard Hybrid Capture 2 when used onsite in rural northern Tanzania","volume":"120","author":"Young","year":"2011","journal-title":"Gynecol Oncol"},{"key":"2021122309580519300_B30","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ijgo.2014.02.026","article-title":"Acceptability of self-collected versus provider-collected sampling for HPV DNA testing among women in rural El Salvador","volume":"126","author":"Rosenbaum","year":"2014","journal-title":"Int J Gynaecol Obstet"},{"key":"2021122309580519300_B31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2013.07.092","article-title":"Self-collection for high-risk HPV detection in Brazilian women using the careHPV\u2122 test","volume":"131","author":"Lorenzi","year":"2013","journal-title":"Gynecol Oncol"},{"key":"2021122309580519300_B32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/1471-2407-11-239","article-title":"Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: An epidemiologic and cost-effectiveness modelling study","volume":"11","author":"Shi","year":"2011","journal-title":"BMC Cancer"},{"key":"2021122309580519300_B33","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S1470-2045(08)70210-9","article-title":"A new HPV-DNA test for cervical-cancer screening in developing regions: A cross-sectional study of clinical accuracy in rural China","volume":"9","author":"Qiao","year":"2008","journal-title":"Lancet Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0447","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0447","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/7\/825\/41876122\/oncolo_21_7_825.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/7\/825\/41876122\/oncolo_21_7_825.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T04:45:08Z","timestamp":1640321108000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/7\/825\/6401397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,17]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,6,17]]},"published-print":{"date-parts":[[2016,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0447","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,7,1]]},"published":{"date-parts":[[2016,6,17]]}}}